Monroe Bank & Trust MI raised its stake in Omnicell, Inc. (NASDAQ:OMCL) by 0.3% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 34,831 shares of the company’s stock after buying an additional 116 shares during the period. Monroe Bank & Trust MI owned approximately 0.09% of Omnicell worth $1,416,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Ameritas Investment Partners Inc. bought a new stake in shares of Omnicell during the first quarter valued at approximately $125,000. LS Investment Advisors LLC increased its stake in shares of Omnicell by 136.3% in the first quarter. LS Investment Advisors LLC now owns 3,571 shares of the company’s stock valued at $145,000 after buying an additional 2,060 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Omnicell by 3.0% in the first quarter. State of Alaska Department of Revenue now owns 4,080 shares of the company’s stock valued at $165,000 after buying an additional 120 shares in the last quarter. Diversified Trust Co purchased a new position in shares of Omnicell during the first quarter valued at $228,000. Finally, Keybank National Association OH purchased a new position in shares of Omnicell during the first quarter valued at $242,000. 96.35% of the stock is owned by institutional investors.
Omnicell, Inc. (OMCL) traded down 1.27% on Monday, reaching $42.80. The company’s stock had a trading volume of 154,850 shares. Omnicell, Inc. has a 12 month low of $30.35 and a 12 month high of $43.50. The company’s market cap is $1.59 billion. The stock’s 50 day moving average price is $41.55 and its 200 day moving average price is $38.06.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, May 4th. The company reported $0.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.36. The business had revenue of $150.90 million for the quarter, compared to analysts’ expectations of $152.63 million. Omnicell had a negative net margin of 1.45% and a positive return on equity of 2.66%. The business’s revenue was down 12.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.35 earnings per share. Equities research analysts forecast that Omnicell, Inc. will post $1.28 earnings per share for the current year.
A number of brokerages have recently commented on OMCL. Cantor Fitzgerald reissued an “overweight” rating and set a $47.00 price objective (up previously from $43.00) on shares of Omnicell in a report on Tuesday, June 13th. BidaskClub raised Omnicell from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 10th. ValuEngine raised Omnicell from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Zacks Investment Research upgraded Omnicell from a “sell” rating to a “hold” rating in a research report on Wednesday, March 1st. Finally, Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $53.00 price objective (up previously from $43.00) on shares of Omnicell in a research report on Tuesday, April 25th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Omnicell presently has an average rating of “Buy” and an average target price of $46.33.
In related news, Director Gary S. Petersmeyer sold 2,200 shares of the stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $41.41, for a total transaction of $91,102.00. Following the transaction, the director now owns 21,075 shares in the company, valued at $872,715.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP J Christopher Drew sold 10,625 shares of the stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $40.97, for a total transaction of $435,306.25. Following the transaction, the vice president now owns 152,057 shares in the company, valued at approximately $6,229,775.29. The disclosure for this sale can be found here. In the last 90 days, insiders sold 69,473 shares of company stock worth $2,869,438. Corporate insiders own 3.75% of the company’s stock.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with our FREE daily email newsletter.